Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

$424.3M

Market Cap • 1/29/2025

2011

(14 years)
Founded

2019

(6 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Fremont

Headquarters • California